The largest database of trusted experimental protocols

Radiotherapy

Radiotherapy is a crucial modality in the treatment of various medical conditions, particularly cancer.
It involves the use of high-energy radiation, such as X-rays, gamma rays, or charged particles, to target and destroy cancer cells while minimizing damage to surrounding healthy tissue.
The goal of radiotherapy is to deliver the most effective radiation dose to the tumor site while sparing normal tissues.
Radiotherapy can be used as a primary treatment, in combination with other therapies (such as chemotherapy or surgery), or as a palliative measure to alleviate symptoms.
The field of radiotherapy is constantly evolving, with new techniques, technologies, and protocols being developed to enhance the precision, safety, and efficacy of this treatment approach.
Understanding the latest advancements in radiotherapy is essential for healthcare professionals and researchers working to improve patient outcomes.

Most cited protocols related to «Radiotherapy»

An observer study was performed on a set of 105 randomly selected chest CT scans obtained in a group of consecutive patients presenting to the emergency ward between March 14th 2020 and March 25th 2020 with suspected SARS-CoV-2 infection, in whom RT-PCR was performed. Patient inclusion, CT protocol, and radiation parameters are described in Supplement 2. Medical ethics committee approval was obtained prior to the study. Informed consent was waived, and data collection and storage were carried out in accordance with local guidelines.
Patient characteristics (age, gender, comorbidities), clinical follow up, including a multidisciplinary clinical diagnosis, if applicable, and RT-PCR results were extracted from electronic patient records. These data allowed stratification of all patients into one of the following three groups: patients with at least one positive RT-PCR result for SARS-CoV-2 within five days after CT (PCR+), patients with one or multiple negative RT-PCR results but a clinical diagnosis of COVID-19 according to clinical records (PCR-/Clinical+), and patients with one or multiple negative RT-PCR results and a clinical course not consistent with COVID-19, or consistent with an alternative diagnosis (PCR-/Clinical-).
Publication 2020
Chest COVID 19 CT protocol Diagnosis Dietary Supplements Ethics Committees Gender Patients Radiotherapy Reverse Transcriptase Polymerase Chain Reaction SARS-CoV-2 X-Ray Computed Tomography

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Aftercare Biopsy Diagnosis Discrimination, Psychology Disease Progression Malignant Neoplasms Needle Biopsies Operative Surgical Procedures Optimism Pathologists Patients Prostatectomy Radiotherapy Recurrence Surgical Margins System, Genitourinary

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Diagnosis Eligibility Determination Ethics Committees, Research Familial Atypical Mole-Malignant Melanoma Syndrome Interferon-alpha Melanoma Neoplasm Metastasis Patients Pharmaceutical Adjuvants Radiotherapy Therapeutics

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Brachytherapy Patient Representatives Prostate Cancer Prostatectomy Radiotherapy
The French national Cartes d'Identité des Tumeurs (CIT) program involves a multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers. Fresh-frozen primary tumor tissue samples were retrospectively collected at the Institut Gustave Roussy (Villejuif), the Hôpital Saint Antoine (Paris), the Hôpital Européen Georges Pompidou (Paris), the Hôpital de Hautepierre (Strasbourg), the Hôpital Purpan (Toulouse), and the Institut Paoli-Calmettes (Marseille), and prospectively collected at the Centre Antoine Lacassagne (Nice). Patients who received preoperative chemotherapy and/or radiation therapy and those with primary rectal cancer were excluded from this study. Clinical and pathologic data were extracted from the medical records and centrally reviewed for the purpose of this study. Patients were staged according to the American Joint Committee on Cancer tumor node metastasis (TNM) staging system [2] and monitored for relapse (distant and/or locoregional recurrence; median follow-up of 51.5 mo). Patient and tumor characteristics are summarized in Table 1 and detailed in Table S1.
Of the 750 tumor samples of the CIT cohort, 566 fulfilled RNA quality requirements for GEP analysis (Figure S1). The 566 samples were split into a discovery set (n = 443) and a validation set (n = 123), well balanced for the main anatomoclinical characteristics (Table 1). The validation set also included 906 CC samples available from seven public datasets (GSE13067, GSE13294, GSE14333, GSE17536/17537, GSE18088, GSE26682, and GSE33113). These datasets corresponded to all available public datasets fulfilling the following criteria: available GEP data obtained using a similar chip platform (Affymetrix U133 Plus 2.0 chips) with raw data CEL files, and tumor location and either common DNA alteration (n = 457) and/or patient outcome (n = 449) data available. Within the discovery (n = 443) and the validation (n = 1,029) sets, 359 and 416 patients with stage II–III CC and documented relapse-free survival (RFS) were available for survival analysis, respectively (Figure S1). The dataset from The Cancer Genome Atlas (TCGA) [13] (link), although obtained using a non-Affymetrix platform and therefore analyzed separately, was added to the validation set because of the extensive DNA alteration annotations provided for 152 CC samples.
Full text: Click here
Publication 2013
DNA Chips Freezing Genome Joints Malignant Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Site Operative Surgical Procedures Patients Pharmacotherapy Radiotherapy Rectal Cancer Recurrence Relapse Tissues

Most recents protocols related to «Radiotherapy»

Not available on PMC !

Example 9

A pediatric patient with Stage IV Wilms tumor is treated with dactinomycin, doxorubicin, cyclophosphamide and vincristine for 65 weeks. Doses of the drugs are as follows: dactinomycin (15 mcg/kg/d [IV]), vincristine (1.5 mg/m 2 wk [IV)), Adriamycin (doxorubicin 20 mg/m2/d [IV]), and cyclophosphamide (10 mg/kg/d [IV]). Dactinomycin courses are given postoperatively and at 13, 26, 39, 52, and 65 weeks. Vincristine is given on days 1 and 8 of each Adriamycin course. Adriamycin is given for three daily doses at 6, 19, 32, 45, and 58 weeks. Cyclophosphamide is given for three daily doses during each Adriamycin and each dactinomycin course except the postoperative dactinomycin course. During each administration of dactinomycin and vincristine a dose of 0.2 cc/kg of DDFPe is administered while the patient breathes supplemental oxygen. *D'angio, Giulio J., et al. “Treatment of Wilms' tumor. Results of the third national Wilms' tumor study.” Cancer 64.2 (1989): 349-360.

Full text: Click here
Patent 2024
Adriamycin Cyclophosphamide Dactinomycin Doxorubicin Malignant Neoplasms Nephroblastoma Oxygen Patients Pharmaceutical Preparations Pharmacotherapy Radiotherapy Vincristine
Not available on PMC !

Example 6

An adult patient with rhabomyosarcoma is treated with IV Vincristine at a dose of 1.4 mg/m2. Concomitantly the patient is administered 0.1 cc kg of DDFPc while breathing room air. Despite breathing room air, increased oxygen levels am still attained in the tumor tissue resulting in increased activity of the drug.

Full text: Click here
Patent 2024
Adult Neoplasms Oxygen Patients Pharmaceutical Preparations Pharmacotherapy Radiotherapy Therapeutics Tissues Vincristine
Not available on PMC !

Example 3

At the time of diagnosis with prostate cancer, subjects are invited to participate in a trial. A subject sample, e.g., blood, is obtained. Periodically, throughout the monitoring, watchful waiting, or active treatment of the subject, e.g., chemotherapy, radiation therapy, e.g., radiation of the prostate, surgery, e.g., surgical prostate resection, hormone therapy, a new subject sample is obtained. At the end of the study, all subject samples are tested for the level of FLNA and/or PSA, and optionally other markers. The subject samples are matched to the medical records of the subjects to correlate FLNA and/or PSA levels, as appropriate, with prostate cancer status at the time of diagnosis, rate of progression of disease, response of subjects to one or more interventions, and transitions between androgen dependent and independent status. Other markers, such as the expression level of keratin 19 and/or filamin B, the age of the subjects, or the prostate volume of the subjects, can also be analyzed in addition to filamin A and/or PSA.

Full text: Click here
Patent 2024
Androgens BLOOD Diagnosis Disease Progression Filamin A Filamin B Hormones Keratin-19 Operative Surgical Procedures Pharmacotherapy Prostate Prostate Cancer Prostatectomy Radiotherapy Therapeutics

Example 2

A 30 year-old female subject with muscle pain in the left leg and joint pain in near the left ankle—is positioned in a 360-degree full body light therapy device. The 360-degree light therapy device is configured as follows: (a) a first type of light emitting diode (LED) emits a wavelength of 550 nm, (b) a second type of LED emits a wavelength of 750 nm, (c) a third type of LED emits a wavelength of about 850 nm, and (d) a fourth type of LED emits a wavelength of about 900 nm.

The light therapy device has: 11520 first LED types (about 25.6% of the total LEDs), 5760 second LED types (about 12.8% of the total LEDs), 21960 third LED types (about 48.8% of the total LEDs), and 11520 fourth LED types (about 25.6% of the total LEDs). The LEDs emit with a power density of about 80 mW/cm2. The LEDs emit power at about 50 Joules/cm2 in a time period of about 10 minutes. The light therapy device is configured to pulse at a rate of about 10 hertz with an 85% duty cycle.

The subject undergoes a 30-minute session of irradiation twice a month for 3 straight months. After the 3 months of treatment, the subject's muscle pain in the left leg mitigates by about 80%, and the subject's joint pain near the left ankle reduces by about 50%.

Full text: Click here
Patent 2024
Aftercare Arthralgia Enzyme Multiplied Immunoassay Technique Joints, Ankle Light Medical Devices Myalgia Pain Phototherapy Pulse Rate Radiotherapy Woman

Example 3

A female patient with cervical carcinoma is treated with combined radiation therapy and chemotherapy+NVX-108. Radiation dosage is 45 Gray (Gy) in 20 fractions followed by low dose-rate intracavitary application of 30 Gy to the cervical region. Chemotherapy consists of intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles. The patient is administered a bolus IV dose of 0.2 cc/kg NVX-108 (2% w/vol DDFPe) 60 minutes prior to each dose of radiation. Follow-up shows complete response to treatment.

Full text: Click here
Patent 2024
Cervical Cancer Cisplatin Neck NVX-108 Oxygen Patients Pharmacotherapy Radiotherapy Woman

Top products related to «Radiotherapy»

Sourced in Germany, United States, Japan, United Kingdom, China, France, India, Greece, Switzerland, Italy
The D8 Advance is a versatile X-ray diffractometer (XRD) designed for phase identification, quantitative analysis, and structural characterization of a wide range of materials. It features advanced optics and a high-performance detector to provide accurate and reliable results.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
Sourced in United States, Canada
The X-RAD 320 is a radiation therapy device that generates X-rays for medical imaging and treatment purposes. It is capable of producing high-energy X-rays for a variety of applications, including diagnostic imaging, image-guided radiation therapy, and small animal research.
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
Sourced in United States, United Kingdom, Germany, Canada, Japan, Sweden, Austria, Morocco, Switzerland, Australia, Belgium, Italy, Netherlands, China, France, Denmark, Norway, Hungary, Malaysia, Israel, Finland, Spain
MATLAB is a high-performance programming language and numerical computing environment used for scientific and engineering calculations, data analysis, and visualization. It provides a comprehensive set of tools for solving complex mathematical and computational problems.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.

More about "Radiotherapy"

Radiotherapy, also known as radiation therapy, is a crucial modality in the treatment of various medical conditions, particularly cancer.
This powerful therapeutic approach involves the use of high-energy radiation, such as X-rays, gamma rays, or charged particles, to target and destroy cancer cells while minimizing damage to surrounding healthy tissue.
The primary goal of radiotherapy is to deliver the most effective radiation dose to the tumor site while sparing normal tissues, ultimately enhancing patient outcomes.
The field of radiotherapy is constantly evolving, with new techniques, technologies, and protocols being developed to improve the precision, safety, and efficacy of this treatment approach.
Healthcare professionals and researchers working in this domain must stay up-to-date with the latest advancements to provide the best possible care for their patients.
One cutting-edge technology used in radiotherapy is the X-RAD 320, a state-of-the-art irradiation system that enables precise and targeted delivery of radiation.
Additionally, the use of RPMI 1640 medium and DMEM (Dulbecco's Modified Eagle Medium) in cell culture experiments can provide valuable insights into the biological effects of radiation on cancer cells, complementing the clinical research on radiotherapy.
Data analysis tools such as SAS version 9.4 and MATLAB can also play a crucial role in radiotherapy research, allowing researchers to analyze complex datasets, model treatment outcomes, and optimize protocols.
Furthermore, the implementation of AI-driven platforms like PubCompare.ai can help identify the most effective radiotherapy protocols and products, enhancing reproducibility and accuracy in this field.
Whether used as a primary treatment, in combination with other therapies like chemotherapy or surgery, or as a palliative measure to alleviate symptoms, radiotherapy remains a cornerstone of modern cancer management.
By staying informed about the latest advancements and leveraging the power of cutting-edge technologies and data analysis tools, healthcare professionals and researchers can continue to improve the lives of patients facing a wide range of medical conditions.